Urologist KOL Profiles Cxbladder
30th July 2019

Pacific Edge (NZX:PEB) and Life Science Ventures hosted a Urology Key Opinion Leader event in New York on 18th July, featuring internationally renowned urologist and USA Key Opinion Leader Dr. Sia Daneshmand Read More

Cxbladder Included in the Latest NCCN Bladder Cancer Guidelines in the USA
15th July 2019

Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer in the USA Read More

Clinical Study Supports Adoption of Cxbladder into New Clinical Pathway
24th June 2019

The latest published clinical paper for Pacific Edge’s Cxbladder bladder cancer tests reveals the cementing evidence behind the introduction of new guidelines for the assessment of haematuriaby one of New Zealand’s largest public healthcare providers, Canterbury District Health Board (DHB) Read More

International Urology Experts Present on Cxbladder
20th May 2019

Pacific Edge Limited (NZX: PEB) is hosting an event today in Auckland, with two internationally renowned urologists presenting on the performance and commercial use of Cxbladder in their USA and New Zealand clinical settings respectively. Read More

Further Compelling Clinical Evidence Supporting Cxbladder
17th May 2019

Cxbladder’s recent diagnostic outperformance has been published in the number one ranked urology journal, European Urology, adding to Cxbladder’s comprehensive clinical evidence for physicians, reimbursers and healthcare providers alike. Read More

Cxbladder Adoption Roll-out Advances in New Zealand
18th March 2019

Public Healthcare provider, Hawke’s Bay District Health Board, to roll out Cxbladder tests Read More